<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the evaluation of the endometrium for malignant or premalignant disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the evaluation of the endometrium for malignant or premalignant disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the evaluation of the endometrium for malignant or premalignant disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah Feldman, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 19, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Evaluation of the endometrium is the key component in the diagnostic evaluation of patients suspected of endometrial carcinoma or a premalignant endometrial lesion (ie, endometrial hyperplasia with or without atypia). Evaluation methods typically include endometrial sampling procedures (eg, endometrial biopsy, dilation and curettage [D&amp;C] with or without hysteroscopy) and/or transvaginal ultrasound [TVUS]. </p><p>This topic will provide an overview of the evaluation of the endometrium for premalignant and malignant disease. Detailed descriptions of the performance of the procedures themselves and the diagnosis of endometrial hyperplasia or carcinoma are available separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3254.html" rel="external">"Endometrial sampling procedures"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3252.html" rel="external">"Saline infusion sonohysterography"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3273.html" rel="external">"Dilation and curettage"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3278.html" rel="external">"Overview of hysteroscopy"</a> and  <a class="medical medical_review" href="/z/d/html/3300.html" rel="external">"Hysteroscopy: Managing fluid and gas distending media"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3217.html" rel="external">"Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis", section on 'Diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening", section on 'Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H3372935014"><span class="h1">HOW TO CHOOSE THE METHOD</span></p><p class="headingAnchor" id="H2796780088"><span class="h2">Postmenopausal patients with bleeding</span><span class="headingEndMark"> — </span>For postmenopausal patients with uterine bleeding, the American College of Obstetricians and Gynecologists and the Society of Radiologists in Ultrasound advises that either endometrial sampling or transvaginal ultrasound (TVUS) can be used as the <strong>first</strong> diagnostic step for evaluating the endometrium [<a href="#rid1">1,2</a>]. The choice of procedure is often driven by the specialty of the physician caring for the patient.</p><p class="bulletIndent1"><span class="glyph">●</span>For those in gynecologic practices, endometrial biopsy is often performed as the initial diagnostic test due to its high sensitivity, low complication rate, and low cost (see <a class="local">'Endometrial biopsy'</a> below). If a cause for the bleeding is determined, then further management depends on the clinical diagnosis.</p><p></p><p class="bulletIndent1">Additional endometrial assessment (with TVUS, repeat endometrial biopsy, or dilation and curettage [D&amp;C] with hysteroscopy) should be performed:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients in whom postmenopausal bleeding continues despite a "benign" endometrial biopsy [<a href="#rid3">3</a>]. Benign endometrial histology includes atrophy (absence of a hormonal effect), proliferative endometrium (estrogen effect), secretory endometrium (progestin effect), disordered or dyssynchronous endometrium (implies irregular shedding of the endometrium secondary to unopposed estrogen), and endometritis. (See  <a class="medical medical_review" href="/z/d/html/16723.html" rel="external">"Endometrial hyperplasia: Management and prognosis", section on 'Proliferative endometrium'</a> and  <a class="medical medical_review" href="/z/d/html/5462.html" rel="external">"Endometritis unrelated to pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When the endometrial biopsy is nondiagnostic, but a high suspicion of cancer remains [<a href="#rid4">4</a>]. Nondiagnostic biopsies may be associated with polyps, fibroids, endometrial carcinoma, or other lesions occupying an area of the uterus that was not sampled.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those in practices where office endometrial biopsy is not performed, TVUS examination is a reasonable initial test. TVUS can also be used for postmenopausal patients in whom office biopsy cannot be performed, structural uterine pathology (eg, polyp, leiomyoma) is suspected, or evaluation of the adnexa is needed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endometrial carcinoma can reasonably be excluded by TVUS in postmenopausal patients with a thin (≤4 mm), homogeneous endometrium on initial evaluation  (<a class="graphic graphic_diagnosticimage graphicRef135035" href="/z/d/graphic/135035.html" rel="external">image 1</a>) [<a href="#rid5">5,6</a>]. (See <a class="local">'Transvaginal ultrasound'</a> below.)</p><p></p><p class="bulletIndent2">However, the diagnostic efficacy of TVUS may be lower in Black patients compared with White patients [<a href="#rid7">7</a>]; the greater prevalence of fibroids (which can limit assessment of the endometrium) in Black patients may contribute to this disparity. The diagnostic efficacy of TVUS is also lower in patients with serous and clear cell endometrial cancers [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/3180.html" rel="external">"Endometrial carcinoma: Serous and clear cell histologies", section on 'Limited role of transvaginal ultrasound'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Further evaluation with endometrial sampling is required if:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The endometrial lining is &gt;4 mm  (<a class="graphic graphic_diagnosticimage graphicRef135034" href="/z/d/graphic/135034.html" rel="external">image 2</a>). Endometrial carcinoma becomes increasingly more frequent relative to benign disease as the endometrial thickness approaches 20 mm, which was the mean endometrial thickness in 759 patients with endometrial carcinoma in one study [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The endometrium is not adequately visualized or shows diffuse or focal heterogeneity.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The patient has persistent bleeding. Persistent bleeding can be a sign of endometrial carcinoma even when the endometrial thickness is ≤4 mm since a thin or indistinct endometrial stripe does not reliably exclude all cancers, particularly those that are of nonendometrioid histology [<a href="#rid9">9,10</a>].</p><p></p><p>Evaluation of postmenopausal patients with bleeding on hormone therapy and postmenopausal patients without bleeding are discussed below. (See <a class="local">'Patients on hormone therapy'</a> below and <a class="local">'Incidental finding on TVUS for another indication'</a> below.)</p><p class="headingAnchor" id="H4190232246"><span class="h2">Premenopausal patients with abnormal bleeding</span><span class="headingEndMark"> — </span>For premenopausal patients with abnormal uterine bleeding (AUB), evaluation of the endometrium with endometrial sampling or TVUS is determined by the bleeding pattern (eg, heavy menstrual bleeding, intermenstrual bleeding, irregular bleeding) and risk factors for endometrial carcinoma  (<a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">table 1</a>). This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'Secondary evaluation'</a>.)</p><p>In contrast with postmenopausal patients, there is no standard threshold for abnormal endometrial thickness in premenopausal patients and the utility of TVUS for excluding endometrial carcinoma in premenopausal patients has not been established [<a href="#rid11">11,12</a>]. If TVUS is performed, it should be performed on days 4, 5, or 6 of the menstrual cycle, ideally when the patient is no longer bleeding. At this early phase of the menstrual cycle, the endometrium is expected to be thin. In reproductive-age patients, normal endometrial thickness in the proliferative phase is 4 to 8 mm and in the secretory phase 8 to 14 mm, but higher values (eg, up to 24 mm) have been reported  (<a class="graphic graphic_diagnosticimage graphicRef51541" href="/z/d/graphic/51541.html" rel="external">image 3</a>) [<a href="#rid4">4,13</a>]. If a patient is found to have a thick, heterogenous echogenic endometrium in the late secretory phase of the menstrual cycle, a follow-up ultrasound early in the next menstrual cycle (after the patient completes their menses) is helpful to reassess the endometrium; the endometrium will frequently appear thin and normal on follow-up. Further evaluation should be based on the clinical situation, including persistent AUB not responsive to medical management or suspicion of a structural abnormality, such as a polyp, which may require removal.</p><p class="headingAnchor" id="H2780521527"><span class="h2">Patients on hormone therapy</span></p><p class="headingAnchor" id="H3455124809"><span class="h3">Continuous combined hormone therapy</span><span class="headingEndMark"> — </span>For pre- and postmenopausal patients on continuous combined estrogen and progestin therapy, the endometrial lining is expected to be thin and atrophic, and in such patients, the initial evaluation of the endometrium is similar to postmenopausal patients with bleeding. (See <a class="local">'Postmenopausal patients with bleeding'</a> above.)</p><p class="headingAnchor" id="H3882964620"><span class="h3">Cyclic progesterone</span><span class="headingEndMark"> — </span>For postmenopausal patients on cyclic <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a>, the endometrium can have a varied appearance and endometrial thickness thresholds are not well established for such patients. TVUS or endometrial sampling may be used for initial evaluation. If ultrasound is used, it is best to perform the ultrasound early in the cycle, when the endometrium is expected to be thin [<a href="#rid14">14</a>]. A homogenous endometrium that is &lt;8 mm is considered normal. However, persistent bleeding <strong>always</strong> requires endometrial sampling regardless of ultrasound findings. We tell patients that bleeding is common when hormone replacement therapy is initiated and should decrease over time. If it does not, and if it becomes heavier, or bleeding occurs after a long period of no bleeding, or at an abnormal time of the cycle, then endometrial sampling is indicated. (See  <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Endometrial monitoring'</a>.)</p><p class="headingAnchor" id="H678011230"><span class="h3">Unopposed estrogen</span><span class="headingEndMark"> — </span>Unopposed estrogen is <strong>contraindicated</strong> in patients with a uterus; the risk of endometrial carcinoma is sufficiently high in such patients. In the rare event that a patient with a uterus is on unopposed estrogen, endometrial biopsy should be performed at least yearly. TVUS may also be useful when a focal endometrial lesion is suspected or when fibroids complicate endometrial assessment.</p><p class="headingAnchor" id="H1260023115"><span class="h3">Tamoxifen</span><span class="headingEndMark"> — </span>For patients on <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> therapy (for the treatment and prevention of breast cancer), routine endometrial assessment is not performed. However, endometrial assessment should be performed if any abnormal bleeding occurs, as tamoxifen confers a slight increase in endometrial carcinoma risk. (See  <a class="medical medical_review" href="/z/d/html/14204.html" rel="external">"Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy"</a>.)</p><p>The choice of procedure (ie, endometrial sampling, TVUS) is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14204.html" rel="external">"Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy", section on 'Pelvic ultrasound and endometrial sampling'</a>.)</p><p class="headingAnchor" id="H3696712396"><span class="h1">METHODS OF EVALUATION</span></p><p class="headingAnchor" id="H2"><span class="h2">Endometrial sampling procedures</span></p><p class="headingAnchor" id="H3"><span class="h3">Endometrial biopsy</span><span class="headingEndMark"> — </span>The development of equipment and techniques for office-based endometrial biopsy has generally replaced the need for diagnostic dilation and curettage (D&amp;C) performed in the operating room [<a href="#rid15">15</a>].</p><p>Advantages of office biopsy include:</p><p class="bulletIndent1"><span class="glyph">●</span>Minimal to no cervical dilation is required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>May be performed without anesthesia or with only local anesthesia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Procedure time is brief; actual sampling time is approximately 5 to 15 seconds.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk of uterine perforation, while low for either procedure, is lower than with D&amp;C. (See  <a class="medical medical_review" href="/z/d/html/3254.html" rel="external">"Endometrial sampling procedures", section on 'Side effects and complications'</a> and  <a class="medical medical_review" href="/z/d/html/3309.html" rel="external">"Uterine perforation during gynecologic procedures", section on 'Uterine perforation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Less expensive than a procedure in the operating room.</p><p></p><p>Disadvantages of office biopsy include:</p><p class="bulletIndent1"><span class="glyph">●</span>It is a "blind procedure," and the operator may (unintentionally) not enter the uterine cavity or sample only the lower uterine segment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>May yield a scant specimen, not reflective of the underlying pathology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>May only sample a portion of the endometrium, particularly in patients with a large uterus, intracavitary fibroids, or uterine anomalies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is usually performed without anesthesia, and patient discomfort may limit the ability to obtain an adequate sample.</p><p></p><p>There is an excellent correlation between the histopathology of endometrial specimens taken by biopsy instruments in the office and D&amp;C [<a href="#rid16">16-18</a>]. However, since less than half of the endometrium is sampled, malignancy can be missed  (<a class="graphic graphic_table graphicRef69145" href="/z/d/graphic/69145.html" rel="external">table 2</a>).</p><p>In a meta-analysis including 39 studies (7914 patients) comparing the results of endometrial biopsy with histopathology at D&amp;C, hysteroscopy, and/or hysterectomy, the Pipelle device was more sensitive for the detection of endometrial carcinoma and hyperplasia with atypia than all other sampling devices; however, the specificity for all devices was high (&gt;98 percent) [<a href="#rid19">19</a>]. In addition, the sensitivity for the diagnosis of endometrial carcinoma (by Pipelle) was higher in postmenopausal compared with premenopausal patients (99.6 versus 91 percent, respectively). Fewer than 5 percent of patients had an insufficient or no sample. In a subsequent meta-analysis assessing the accuracy of outpatient endometrial biopsy in the diagnosis of endometrial carcinoma, the post-test probability of endometrial carcinoma after a positive biopsy was 82 percent (95% CI 60-93 percent) and, after a negative test, was 0.9 percent (95% CI 0.4-2.4 percent) [<a href="#rid20">20</a>]. In this analysis, 15 percent (138 of 945) of specimens were inadequate (no sample or insufficient tissue for assessment), and one case of cancer was subsequently found among these patients.</p><p>All sampling devices perform better when pathology is global rather than focal; this has been demonstrated repeatedly in multiple studies. In a prospective study including 65 patients with known endometrial carcinoma undergoing Pipelle biopsy prior to hysterectomy, endometrial sampling was most reliable when at least one-half of the endometrium was affected by disease [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Dilation and curettage</span><span class="headingEndMark"> — </span>As discussed above, endometrial biopsy in the office has generally replaced diagnostic D&amp;C, but there is still a role for this procedure for some patients.</p><p>Indications for diagnostic D&amp;C include (see  <a class="medical medical_review" href="/z/d/html/3273.html" rel="external">"Dilation and curettage"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>When an office endometrial biopsy cannot be performed (eg, cervical stenosis, patient anxiety or pain). (See  <a class="medical medical_review" href="/z/d/html/3254.html" rel="external">"Endometrial sampling procedures", section on 'Preprocedure preparation'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After a nondiagnostic (eg, insufficient tissue) office biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When transvaginal ultrasound (TVUS) identifies a focal lesion or multiple lesions, which may not be adequately sampled by office biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with persistent abnormal bleeding, even if benign histology was demonstrated on a prior office biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When a concomitant operative procedure, such as laparoscopy, is deemed necessary.</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Role of hysteroscopy</span><span class="headingEndMark"> — </span>For patients undergoing D&amp;C and in whom the risk for endometrial carcinoma is increased  (<a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">table 1</a>), we advise also performing a diagnostic hysteroscopy; however, hysteroscopy should <strong>not</strong> be performed instead of D&amp;C. This approach is consistent with guidelines from the Society of Gynecologic Oncology [<a href="#rid22">22</a>]. Hysteroscopy provides direct visualization of the endometrial cavity, thereby allowing targeted biopsy or excision of lesions prior to curettage of the background endometrium [<a href="#rid22">22</a>].</p><p>Multiple studies have shown that diagnostic hysteroscopy can aid in the detection of focal lesions of the endometrial lining that may be missed by D&amp;C alone (approximately 60 percent of curettage specimens sample less than half of the uterine cavity [<a href="#rid23">23</a>]) [<a href="#rid24">24,25</a>]. However, hysteroscopy can also miss endometrial carcinoma. In one descriptive study including 29 patients with endometrial carcinoma, the diagnosis was missed in 10 patients (34.5 percent) using hysteroscopy alone (without biopsies) [<a href="#rid26">26</a>].</p><p>Hysteroscopy with biopsies requires more skill and is more costly and invasive than most other modalities of endometrial assessment [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/3278.html" rel="external">"Overview of hysteroscopy"</a>.)</p><p class="headingAnchor" id="H1830089598"><span class="h4">Risk of tumor dissemination</span><span class="headingEndMark"> — </span>One concern with hysteroscopy is the risk of possible cancer dissemination due to the intraperitoneal spillage of endometrial cells (some of which remain viable) through the fallopian tubes [<a href="#rid27">27-39</a>]. </p><p>The clinical significance of the transport of these cells is not known, nor does it necessarily result in implantation and/or persistence of disease. While peritoneal washings are not part of the staging of endometrial carcinoma  (<a class="graphic graphic_table graphicRef141918" href="/z/d/graphic/141918.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef141963" href="/z/d/graphic/141963.html" rel="external">table 4</a>), they were in the past, and the presence of cancer cells in the peritoneal cavity may affect prognosis (see  <a class="medical medical_review" href="/z/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment", section on 'Staging system'</a>). However, in a meta-analysis of observational studies including patients with endometrial carcinoma, patients who had or had not undergone diagnostic hysteroscopy had similar rates of positive peritoneal cytology [<a href="#rid39">39</a>]. In addition, in a subsequent retrospective study that reported on long-term follow-up (median 25 months), prestaging hysteroscopy was not associated with worse survival [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Transvaginal ultrasound</span><span class="headingEndMark"> — </span>TVUS is an acceptable alternative to endometrial sampling in some patients, and also allows for evaluation of the adnexa and structural lesions of the endometrium (eg, polyp, leiomyoma), if present. Sonographic measurement of endometrial thickness is performed by scanning the uterus in a sagittal view. The result reported is the double layer endometrial thickness measured in an anteroposterior dimension from one basalis layer to the other, excluding any fluid within the cavity.</p><p>The use of TVUS as an alternative to endometrial sampling is supported by a meta-analysis of 35 prospective studies that included data from almost 6000 patients with postmenopausal bleeding [<a href="#rid41">41</a>]. The sensitivity of TVUS for detection of endometrial carcinoma at a thickness of 4 and 5 mm was 96 percent; the specificity was 53 and 61 percent, respectively. The authors of this analysis calculated that the probability of endometrial carcinoma (based on the average risk associated with postmenopausal bleeding) following a normal (&lt;5 mm endometrial thickness) TVUS was 1 percent.</p><p>However, subsequent meta-analyses have reached different conclusions.</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis using individual patient data from 13 studies including almost 3000 patients, the sensitivity of TVUS for detection of endometrial carcinoma at 5 mm, 4 mm, and 3 mm, was 90, 95, and 98 percent, respectively [<a href="#rid42">42</a>]. A limitation of this analysis was that many studies were excluded because individual patient data were not available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another meta-analysis consisted of 57 studies with 9031 patients [<a href="#rid43">43</a>]. The four highest quality studies used an endometrial thickness threshold of ≤5 mm. Using the pooled estimates from these four studies only, a positive test result raised the probability of cancer from 14 to 31 percent, while a negative test reduced it to 2.5 percent. The authors concluded that while a negative result (≤5 mm) usually excluded endometrial neoplasia, the measurement of endometrial thickness alone could not be used to reliably exclude cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of nine studies (3483 patients without endometrial carcinoma and 330 with the disease) found that when the detection rate for endometrial carcinoma was 63 percent (95% CI 58-69 percent), the false-positive rate was 10 percent; by contrast, when the detection rate increased to 96 percent (95% CI 94-98 percent), the false-positive rate increased to 50 percent [<a href="#rid44">44</a>]. The authors concluded that even at this latter threshold, 4 percent of endometrial carcinomas would be missed; thus, further invasive diagnostic testing was indicated in all symptomatic patients with a "thin" endometrial thickness.</p><p></p><p>For patients in whom TVUS visualization of the endometrium is limited (eg, large, fibroid uterus), additional methods of evaluation may be needed.  </p><p class="headingAnchor" id="H2723317941"><span class="h2">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">Saline</a><strong> infusion sonography</strong> – Saline infusion sonography (SIS; also called sonohysterography) is generally not used for the primary evaluation of the endometrium; rather, SIS may be used as subsequent evaluation to help detect small lesions (eg, polyps, small submucous fibroids) that may be missed on TVUS or by blind endometrial sampling. One of the main disadvantages of SIS is that no tissue is obtained for histologic diagnosis. (See  <a class="medical medical_review" href="/z/d/html/3252.html" rel="external">"Saline infusion sonohysterography", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1">The combined technique of endometrial biopsy and SIS helps diagnose the cause of abnormal uterine bleeding (AUB) in most patients without the need for more invasive procedures such as hysteroscopy with D&amp;C [<a href="#rid45">45,46</a>]. In a prospective study including 113 patients ages 25 to 69 years with AUB evaluated with endometrial biopsy and SIS and then subsequently with hysteroscopy/curettage or hysterectomy, the sensitivity, specificity, and positive and negative predictive values of biopsy plus SIS were 97, 70, 82, and 94 percent, respectively [<a href="#rid45">45</a>]. False-positive results were due to intrauterine debris, blood clot, thickened endometrial folds, and misidentified endometrial fragments. A subsequent meta-analysis showed similar results [<a href="#rid47">47</a>]. The combined technique is most useful in patients with a symmetrically thickened endometrium. If SIS shows a focal lesion, hysteroscopy with targeted biopsies should be considered. (See <a class="local">'Role of hysteroscopy'</a> above.)</p><p></p><p class="bulletIndent1">As with hysteroscopy, dissemination of cancer is a theoretical concern, but the clinical significance is not known. This is discussed in detail separately. (See <a class="local">'Risk of tumor dissemination'</a> above and  <a class="medical medical_review" href="/z/d/html/3252.html" rel="external">"Saline infusion sonohysterography", section on 'Dissemination of carcinoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Computed tomography (CT) or magnetic resonance imaging (MRI)</strong> – CT and MRI are also not routinely used for the primary evaluation of the endometrium. Normal endometrial thickness on CT for a postmenopausal patient is not well established and abnormalities of the endometrium noted on CT should be further evaluated with TVUS (see <a class="local">'Transvaginal ultrasound'</a> above). By contrast, the normal postmenopausal endometrium on MRI should be hyperintense on T2-weighted images and &lt;5 mm thick [<a href="#rid48">48</a>], with the exception of patients on hormonal therapy. Abnormalities of the endometrium on MRI should be further evaluated with endometrial sampling. (See <a class="local">'Endometrial sampling procedures'</a> above.).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational</strong> <strong>methods</strong> – Methylated DNA, obtained from a tampon, vaginal fluid, or cervical sample, has been proposed as an initial method to detect endometrial cancers in patients with abnormal uterine or postmenopausal bleeding [<a href="#rid49">49,50</a>]. This method of evaluation is considered investigational. Other investigational methods are mentioned separately. (See  <a class="medical medical_review" href="/z/d/html/3254.html" rel="external">"Endometrial sampling procedures", section on 'Investigational approaches'</a>.)</p><p></p><p class="headingAnchor" id="H2834626672"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H3931288952"><span class="h2">Incidental finding on TVUS for another indication</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postmenopausal patients</strong> – In a postmenopausal patient without bleeding in whom an ultrasound examination was performed for another indication other than evaluation of the endometrium, the finding of a thickened endometrium, a focal endometrial mass, or fluid within the endometrial cavity may require further evaluation. While most patients with endometrial carcinoma present with abnormal uterine bleeding (AUB), approximately 5 to 20 percent patients without bleeding will be diagnosed with cancer [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endometrial thickness &gt;4 mm </strong>– In our practice, we sample the endometrium for postmenopausal patients without uterine bleeding in whom the endometrial thickness is &gt;4 mm. However, expert opinion varies, and higher thresholds have been described. Many patients with an endometrial thickness of &gt;4 mm will have benign pathology (eg, endometrial polyp, submucosal fibroid) and other findings on transvaginal ultrasound (TVUS) may provide reassurance. For example, a single feeding vessel (which may arborize) may be visualized with Doppler, which is reassuring for an endometrial polyp, or the endometrium may "wrap" around a submucosal fibroid, resulting in a thickened appearance. </p><p></p><p class="bulletIndent2">Endometrial thickness is less predictive of endometrial neoplasia in asymptomatic patients (those without postmenopausal uterine bleeding [including red, pink, or brown spotting or staining]). In a meta-analysis of 32 studies including over 11,000 asymptomatic postmenopausal patients who were not using hormone therapy, mean endometrial thickness was 2.9 mm [<a href="#rid52">52</a>]. The sensitivity and specificity for detecting endometrial carcinoma at an endometrial thickness of ≥5 mm was 83 and 72 percent, respectively; this is lower than in patients with bleeding. There were few data for an endometrial thickness &gt;5 mm. A well-designed decision analysis calculated that postmenopausal patients without uterine bleeding who had an endometrial thickness &gt;11 mm had an endometrial carcinoma risk of 6.7 percent; this risk is similar to postmenopausal patients with bleeding and an endometrial thickness &gt;5 mm [<a href="#rid51">51</a>]. However, lower thresholds have been described. In a meta-analysis of 18 studies evaluating the diagnostic accuracy of TVUS in over 10,300 postmenopausal patients without bleeding, a threshold of 3 to 5.9 mm had the highest sensitivity (0.81, 95% CI, 0.49-0.85; eight studies) for detecting atypical endometrial hyperplasia and endometrial carcinoma, while a threshold of ≥14 mm had the highest specificity (0.86, 95% CI 0.71-0.94; five studies) [<a href="#rid53">53</a>]. The overall incidence of endometrial pathology was low for both groups. While less pathology was missed in the lower threshold group, more patients had false-positive results which may lead to unnecessary procedures (ie, endometrial sampling), increased cost, and unfavorable patient experiences. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endometrial fluid</strong> – We also sample selected postmenopausal patients without uterine bleeding if endometrial fluid is visualized on ultrasound. In patients with cervical stenosis, a patient might be bleeding into the endometrial cavity, but the blood and/or tissue is unable to pass through the cervical os. Such patients are at increased risk of endometrial carcinoma [<a href="#rid54">54-58</a>]. The surrounding endometrium should be assessed for focal lesions, and the two layers of endometrium combined into a single endometrial thickness. (See <a class="local">'Transvaginal ultrasound'</a> above.)</p><p></p><p class="bulletIndent2">In our practice, we typically perform endometrial sampling in postmenopausal patients with endometrial fluid and an endometrial thickness &gt;4 mm. While a "sliver" of fluid within the endometrial cavity is a normal finding [<a href="#rid54">54,55,59</a>], more than this is concerning for bleeding (with the blood not able to pass through a stenotic cervix), especially in a patient using an anticoagulant. By contrast, a thin (≤4 mm) atrophic endometrium (without any focal lesions) surrounding the endometrial fluid is a reassuring finding.</p><p></p><p class="bulletIndent1">Postmenopausal patients without bleeding on hormone therapy are managed similarly to postmenopausal patients with bleeding on hormone therapy and are described in detail above. (See <a class="local">'Patients on hormone therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premenopausal patients</strong> –<strong> </strong>In asymptomatic premenopausal patients without AUB, endometrial thickness alone is not an indication for biopsy. Endometrial evaluation should be based on a combination of factors  (<a class="graphic graphic_table graphicRef58600" href="/z/d/graphic/58600.html" rel="external">table 5</a>), including cervical cytology results showing glandular abnormalities or endometrial cells, a chronic history of estrogen excess or anovulation (polycystic ovary syndrome), focal endometrial lesions, as well as endometrial thickness.</p><p></p><p class="headingAnchor" id="H2394224285"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/121144.html" rel="external">"Society guideline links: Uterine cancer"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/866.html" rel="external">"Patient education: Endometrial cancer diagnosis, staging, and surgical treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/8401.html" rel="external">"Patient education: Abnormal uterine bleeding (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Evaluation of the endometrium (with endometrial sampling and/or transvaginal ultrasound [TVUS]) is the key component in the diagnostic evaluation of patients suspected of endometrial carcinoma or a premalignant endometrial lesion. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postmenopausal patients with bleeding and patients (pre- and postmenopausal) on hormone therapy with abnormal bleeding</strong> (see <a class="local">'Postmenopausal patients with bleeding'</a> above and <a class="local">'Patients on hormone therapy'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For such patients evaluated in a gynecologic practice, endometrial biopsy is often performed as the initial diagnostic test due to its high sensitivity, low complication rate, and low cost. </p><p></p><p class="bulletIndent2">Additional endometrial assessment (with TVUS, repeat endometrial biopsy, or dilation and curettage [D&amp;C] with hysteroscopy) is performed in patients with persistent bleeding despite a "benign" endometrial biopsy and in patients with a nondiagnostic endometrial biopsy but in whom a high suspicion of cancer remains.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For such patients evaluated in a practice where office endometrial biopsy is not performed, TVUS examination is a reasonable initial test. TVUS can also be used as an initial test for patients in whom office biopsy cannot be performed, structural uterine pathology (eg, polyp, leiomyoma) is suspected, or evaluation of the adnexa is needed.</p><p></p><p class="bulletIndent2">Further evaluation with endometrial sampling is required if the endometrial lining is &gt;4 mm (postmenopausal patients), the endometrium is not adequately visualized or shows diffuse or focal heterogeneity, or in patients with persistent bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premenopausal patients with abnormal bleeding</strong> – Premenopausal patients with abnormal bleeding are evaluated with endometrial sampling or TVUS; the choice of method is determined by the bleeding pattern (eg, heavy menstrual bleeding, intermenstrual bleeding, irregular bleeding) and risk factors for endometrial carcinoma  (<a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">table 1</a>). (See <a class="local">'Premenopausal patients with abnormal bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methods of evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endometrial sampling has generally replaced the need for diagnostic D&amp;C in the operating room; there is an excellent correlation between the histopathology of endometrial specimens taken by these methods [<a href="#rid16">16-18</a>]. However, since less than half of the endometrium is sampled, malignancy can be missed. (See <a class="local">'Endometrial biopsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients undergoing D&amp;C and in whom the risk for endometrial carcinoma is increased  (<a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">table 1</a>), we advise also performing a<strong> </strong>diagnostic hysteroscopy to aid in the detection of focal lesions of the endometrial lining that may be missed by D&amp;C alone. (See <a class="local">'Role of hysteroscopy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TVUS also allows for evaluation of the adnexa and structural lesions of the endometrium (eg, polyp, leiomyoma), if present. However, the diagnostic efficacy of TVUS may be lower in Black patients compared with White patients; greater prevalence of fibroids in Black patients may contribute to this disparity. (See <a class="local">'Transvaginal ultrasound'</a> above and <a class="local">'Postmenopausal patients with bleeding'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other methods, such as <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> infusion sonography (SIS; also called sonohysterography), computed tomography (CT), and magnetic resonance imaging (MRI) are generally not used for the primary evaluation of the endometrium. (See <a class="local">'Other'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without bleeding</strong> – In postmenopausal patients without bleeding in whom an ultrasound examination was performed for another indication other than evaluation of the endometrium, the finding of a thickened endometrium or fluid within the endometrial cavity may require further evaluation. In premenopausal patients without abnormal bleeding, endometrial thickness alone is not an indication for biopsy. (See <a class="local">'Incidental finding on TVUS for another indication'</a> above.)</p><p></p><p class="headingAnchor" id="H2140987413"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Deborah Levine, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Goldstein RB, Bree RL, Benson CB, et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement. J Ultrasound Med 2001; 20:1025.</a></li><li><a class="nounderline abstract_t">ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol 2018; 131:e124. Reaffirmed 2023.</a></li><li><a class="nounderline abstract_t">Clark TJ, Mann CH, Shah N, et al. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. Acta Obstet Gynecol Scand 2001; 80:784.</a></li><li class="breakAll">APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.</li><li><a class="nounderline abstract_t">Goldstein SR, Nachtigall M, Snyder JR, Nachtigall L. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 1990; 163:119.</a></li><li><a class="nounderline abstract_t">Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding--a Nordic multicenter study. Am J Obstet Gynecol 1995; 172:1488.</a></li><li><a class="nounderline abstract_t">Doll KM, Romano SS, Marsh EE, Robinson WR. Estimated Performance of Transvaginal Ultrasonography for Evaluation of Postmenopausal Bleeding in a Simulated Cohort of Black and White Women in the US. JAMA Oncol 2021; 7:1158.</a></li><li><a class="nounderline abstract_t">Saccardi C, Spagnol G, Bonaldo G, et al. New Light on Endometrial Thickness as a Risk Factor of Cancer: What Do Clinicians Need to Know? Cancer Manag Res 2022; 14:1331.</a></li><li><a class="nounderline abstract_t">Wang J, Wieslander C, Hansen G, et al. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol 2006; 101:120.</a></li><li><a class="nounderline abstract_t">Chandavarkar U, Kuperman J, Muderspach L, et al. Postmenopausal endometrial cancer: Reevaluating the role of endometrial echo complex. Gynecol Oncol 2011; 120:S11.</a></li><li><a class="nounderline abstract_t">Dijkhuizen FP, Brölmann HA, Potters AE, et al. The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities. Obstet Gynecol 1996; 87:345.</a></li><li><a class="nounderline abstract_t">Breitkopf DM, Frederickson RA, Snyder RR. Detection of benign endometrial masses by endometrial stripe measurement in premenopausal women. Obstet Gynecol 2004; 104:120.</a></li><li><a class="nounderline abstract_t">Goldstein SR, Zeltser I, Horan CK, et al. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol 1997; 177:102.</a></li><li><a class="nounderline abstract_t">Levine D, Gosink BB, Johnson LA. Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy. Radiology 1995; 197:603.</a></li><li><a class="nounderline abstract_t">Grimes DA. Diagnostic dilation and curettage: a reappraisal. Am J Obstet Gynecol 1982; 142:1.</a></li><li><a class="nounderline abstract_t">Lipscomb GH, Lopatine SM, Stovall TG, Ling FW. A randomized comparison of the Pipelle, Accurette, and Explora endometrial sampling devices. Am J Obstet Gynecol 1994; 170:591.</a></li><li><a class="nounderline abstract_t">Silver MM, Miles P, Rosa C. Comparison of Novak and Pipelle endometrial biopsy instruments. Obstet Gynecol 1991; 78:828.</a></li><li><a class="nounderline abstract_t">Stovall TG, Solomon SK, Ling FW. Endometrial sampling prior to hysterectomy. Obstet Gynecol 1989; 73:405.</a></li><li><a class="nounderline abstract_t">Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000; 89:1765.</a></li><li><a class="nounderline abstract_t">Clark TJ, Mann CH, Shah N, et al. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG 2002; 109:313.</a></li><li><a class="nounderline abstract_t">Guido RS, Kanbour-Shakir A, Rulin MC, Christopherson WA. Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer. J Reprod Med 1995; 40:553.</a></li><li><a class="nounderline abstract_t">Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. Obstet Gynecol 2012; 120:1160.</a></li><li><a class="nounderline abstract_t">Stock RJ, Kanbour A. Prehysterectomy curettage. Obstet Gynecol 1975; 45:537.</a></li><li><a class="nounderline abstract_t">Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand 2001; 80:1131.</a></li><li><a class="nounderline abstract_t">Gimpelson RJ, Rappold HO. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases. Am J Obstet Gynecol 1988; 158:489.</a></li><li><a class="nounderline abstract_t">Deckardt R, Lueken RP, Gallinat A, et al. Comparison of transvaginal ultrasound, hysteroscopy, and dilatation and curettage in the diagnosis of abnormal vaginal bleeding and intrauterine pathology in perimenopausal and postmenopausal women. J Am Assoc Gynecol Laparosc 2002; 9:277.</a></li><li><a class="nounderline abstract_t">Alcázar JL, Errasti T, Zornoza A. Saline infusion sonohysterography in endometrial cancer: assessment of malignant cells dissemination risk. Acta Obstet Gynecol Scand 2000; 79:321.</a></li><li><a class="nounderline abstract_t">Dessole S, Rubattu G, Farina M, et al. Risks and usefulness of sonohysterography in patients with endometrial carcinoma. Am J Obstet Gynecol 2006; 194:362.</a></li><li><a class="nounderline abstract_t">Berry E, Lindheim SR, Connor JP, et al. Sonohysterography and endometrial cancer: incidence and functional viability of disseminated malignant cells. Am J Obstet Gynecol 2008; 199:240.e1.</a></li><li><a class="nounderline abstract_t">Obermair A, Geramou M, Gucer F, et al. Does hysteroscopy facilitate tumor cell dissemination? Incidence of peritoneal cytology from patients with early stage endometrial carcinoma following dilatation and curettage (D &amp; C) versus hysteroscopy and D &amp; C. Cancer 2000; 88:139.</a></li><li><a class="nounderline abstract_t">Egarter C, Krestan C, Kurz C. Abdominal dissemination of malignant cells with hysteroscopy. Gynecol Oncol 1996; 63:143.</a></li><li><a class="nounderline abstract_t">Sagawa T, Yamada H, Sakuragi N, Fujimoto S. A comparison between the preoperative and operative findings of peritoneal cytology in patients with endometrial cancer. Asia Oceania J Obstet Gynaecol 1994; 20:39.</a></li><li><a class="nounderline abstract_t">Bradley WH, Boente MP, Brooker D, et al. Hysteroscopy and cytology in endometrial cancer. Obstet Gynecol 2004; 104:1030.</a></li><li><a class="nounderline abstract_t">Kuzel D, Tóth D, Kobilková J, Dohnalová A. Peritoneal washing cytology on fluid hysteroscopy and after curettage in women with endometrial carcinoma. Acta Cytol 2001; 45:931.</a></li><li><a class="nounderline abstract_t">Lo KW, Cheung TH, Yim SF, Chung TK. Hysteroscopic dissemination of endometrial carcinoma using carbon dioxide and normal saline: a retrospective study. Gynecol Oncol 2002; 84:394.</a></li><li><a class="nounderline abstract_t">Gu M, Shi W, Huang J, et al. Association between initial diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with endometrial carcinoma. Cancer 2000; 90:143.</a></li><li><a class="nounderline abstract_t">Arikan G, Reich O, Weiss U, et al. Are endometrial carcinoma cells disseminated at hysteroscopy functionally viable? Gynecol Oncol 2001; 83:221.</a></li><li><a class="nounderline abstract_t">Takac I. Saline infusion sonohysterography and the risk of malignant extrauterine spread in endometrial cancer. Ultrasound Med Biol 2008; 34:7.</a></li><li><a class="nounderline abstract_t">Yazbeck C, Dhainaut C, Batallan A, et al. [Diagnostic hysteroscopy and risk of peritoneal dissemination of tumor cells]. Gynecol Obstet Fertil 2005; 33:247.</a></li><li><a class="nounderline abstract_t">Ben-Arie A, Tamir S, Dubnik S, et al. Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer? Int J Gynecol Cancer 2008; 18:813.</a></li><li><a class="nounderline abstract_t">Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998; 280:1510.</a></li><li><a class="nounderline abstract_t">Timmermans A, Opmeer BC, Khan KS, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 2010; 116:160.</a></li><li><a class="nounderline abstract_t">Gupta JK, Chien PF, Voit D, et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand 2002; 81:799.</a></li><li><a class="nounderline abstract_t">Tabor A, Watt HC, Wald NJ. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol 2002; 99:663.</a></li><li><a class="nounderline abstract_t">Mihm LM, Quick VA, Brumfield JA, et al. The accuracy of endometrial biopsy and saline sonohysterography in the determination of the cause of abnormal uterine bleeding. Am J Obstet Gynecol 2002; 186:858.</a></li><li><a class="nounderline abstract_t">Krampl E, Bourne T, Hurlen-Solbakken H, Istre O. Transvaginal ultrasonography sonohysterography and operative hysteroscopy for the evaluation of abnormal uterine bleeding. Acta Obstet Gynecol Scand 2001; 80:616.</a></li><li><a class="nounderline abstract_t">de Kroon CD, de Bock GH, Dieben SW, Jansen FW. Saline contrast hysterosonography in abnormal uterine bleeding: a systematic review and meta-analysis. BJOG 2003; 110:938.</a></li><li><a class="nounderline abstract_t">Langer JE, Oliver ER, Lev-Toaff AS, Coleman BG. Imaging of the female pelvis through the life cycle. Radiographics 2012; 32:1575.</a></li><li><a class="nounderline abstract_t">Evans I, Reisel D, Jones A, et al. Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK. Lancet Oncol 2023; 24:1375.</a></li><li><a class="nounderline abstract_t">Bakkum-Gamez JN, Sherman ME, Slettedahl SW, et al. Detection of endometrial cancer using tampon-based collection and methylated DNA markers. Gynecol Oncol 2023; 174:11.</a></li><li><a class="nounderline abstract_t">Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004; 24:558.</a></li><li><a class="nounderline abstract_t">Breijer MC, Peeters JA, Opmeer BC, et al. Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2012; 40:621.</a></li><li><a class="nounderline abstract_t">Vitale SG, Riemma G, Haimovich S, et al. Risk of endometrial cancer in asymptomatic postmenopausal women in relation to ultrasonographic endometrial thickness: systematic review and diagnostic test accuracy meta-analysis. Am J Obstet Gynecol 2023; 228:22.</a></li><li><a class="nounderline abstract_t">Debby A, Malinger G, Glezerman M, Golan A. Intra-uterine fluid collection in postmenopuasal women with cervical stenosis. Maturitas 2006; 55:334.</a></li><li><a class="nounderline abstract_t">Schmidt T, Nawroth F, Breidenbach M, et al. Differential indication for histological evaluation of endometrial fluid in postmenopause. Maturitas 2005; 50:177.</a></li><li><a class="nounderline abstract_t">Vuento MH, Pirhonen JP, Mäkinen JI, et al. Endometrial fluid accumulation in asymptomatic postmenopausal women. Ultrasound Obstet Gynecol 1996; 8:37.</a></li><li><a class="nounderline abstract_t">Pardo J, Kaplan B, Nitke S, et al. Postmenopausal intrauterine fluid collection: correlation between ultrasound and hysteroscopy. Ultrasound Obstet Gynecol 1994; 4:224.</a></li><li><a class="nounderline abstract_t">Zalel Y, Tepper R, Cohen I, et al. Clinical significance of endometrial fluid collections in asymptomatic postmenopausal women. J Ultrasound Med 1996; 15:513.</a></li><li><a class="nounderline abstract_t">Goldstein SR. Postmenopausal endometrial fluid collections revisited: look at the doughnut rather than the hole. Obstet Gynecol 1994; 83:738.</a></li></ol></div><div id="topicVersionRevision">Topic 3232 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587008" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29683909" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11531627" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11531627" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2197861" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7755059" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding--a Nordic multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34264304" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Estimated Performance of Transvaginal Ultrasonography for Evaluation of Postmenopausal Bleeding in a Simulated Cohort of Black and White Women in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35401014" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : New Light on Endometrial Thickness as a Risk Factor of Cancer: What Do Clinicians Need to Know?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16307792" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Postmenopausal endometrial cancer: Reevaluating the role of endometrial echo complex</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8598952" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229010" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Detection of benign endometrial masses by endometrial stripe measurement in premenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9240591" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7480726" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7055159" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diagnostic dilation and curettage: a reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8116719" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A randomized comparison of the Pipelle, Accurette, and Explora endometrial sampling devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1923207" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of Novak and Pipelle endometrial biopsy instruments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2915864" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Endometrial sampling prior to hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11042572" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11950187" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7473450" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23090535" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Management of endometrial precancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1124168" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prehysterectomy curettage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11846711" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3348309" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12101322" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of transvaginal ultrasound, hysteroscopy, and dilatation and curettage in the diagnosis of abnormal vaginal bleeding and intrauterine pathology in perimenopausal and postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10746850" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Saline infusion sonohysterography in endometrial cancer: assessment of malignant cells dissemination risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16458630" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risks and usefulness of sonohysterography in patients with endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456240" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sonohysterography and endometrial cancer: incidence and functional viability of disseminated malignant cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10618616" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Does hysteroscopy facilitate tumor cell dissemination? Incidence of peritoneal cytology from patients with early stage endometrial carcinoma following dilatation and curettage (D&amp;C) versus hysteroscopy and D&amp;C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8898185" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Abdominal dissemination of malignant cells with hysteroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8172526" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A comparison between the preoperative and operative findings of peritoneal cytology in patients with endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15516397" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hysteroscopy and cytology in endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11726120" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Peritoneal washing cytology on fluid hysteroscopy and after curettage in women with endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11855876" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hysteroscopic dissemination of endometrial carcinoma using carbon dioxide and normal saline: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10896327" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Association between initial diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11606075" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Are endometrial carcinoma cells disseminated at hysteroscopy functionally viable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17689177" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Saline infusion sonohysterography and the risk of malignant extrauterine spread in endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894211" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : [Diagnostic hysteroscopy and risk of peritoneal dissemination of tumor cells].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17961159" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9809732" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20567183" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12225294" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12039131" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015495" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The accuracy of endometrial biopsy and saline sonohysterography in the determination of the cause of abnormal uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11437719" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Transvaginal ultrasonography sonohysterography and operative hysteroscopy for the evaluation of abnormal uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14550365" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Saline contrast hysterosonography in abnormal uterine bleeding: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23065159" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Imaging of the female pelvis through the life cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37944542" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37141817" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Detection of endometrial cancer using tampon-based collection and methylated DNA markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15386607" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23001905" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35932873" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Risk of endometrial cancer in asymptomatic postmenopausal women in relation to ultrasonographic endometrial thickness: systematic review and diagnostic test accuracy meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16839716" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intra-uterine fluid collection in postmenopuasal women with cervical stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15734598" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Differential indication for histological evaluation of endometrial fluid in postmenopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8843618" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Endometrial fluid accumulation in asymptomatic postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12797186" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Postmenopausal intrauterine fluid collection: correlation between ultrasound and hysteroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8803865" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical significance of endometrial fluid collections in asymptomatic postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164935" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Postmenopausal endometrial fluid collections revisited: look at the doughnut rather than the hole.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
